Cargando…
Role of CTSA institutes and academic medical centers in facilitating preapproval access to investigational agents and devices during the COVID-19 pandemic
INTRODUCTION: With no approved treatments for COVID-19 initially available, the Food and Drug Administration utilized multiple preapproval pathways to provide access to investigational agents and/or medical devices: Expanded Access, Emergency Use Authorizations, and Clinical Trials. Regulatory units...
Autores principales: | Gravelin, Misty, Wright, Jeanne, Holbein, M.E. Blair, Berro, Marlene, Brown, Jennifer S., Mashour, George A., Weatherwax, Kevin J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cambridge University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8134898/ https://www.ncbi.nlm.nih.gov/pubmed/34192051 http://dx.doi.org/10.1017/cts.2021.15 |
Ejemplares similares
-
Right now, in the right way: U. S. Food and Drug Administration’s expanded access program and patient rights
por: Holbein, M. E. Blair, et al.
Publicado: (2018) -
2276 Development of the expanded access oversight committee at Michigan Medicine
por: Weatherwax, Kevin, et al.
Publicado: (2018) -
400 Exploring the Diversity of Expanded Access Patients at Michigan Medicine
por: Gravelin, Misty, et al.
Publicado: (2023) -
National landscape assessment of academic medical center support for expanded access to investigational products
por: Gravelin, Misty, et al.
Publicado: (2022) -
Adapting an Expanded Access program to enable investigational treatments for COVID-19
por: Samuels, Elias, et al.
Publicado: (2022)